Analyst Price Targets — VRDN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 8, 2026 12:29 pm | — | Truist Financial | $36.00 | $14.47 | TheFly | Viridian Therapeutics price target lowered to $36 from $40 at Truist |
| April 8, 2026 11:45 am | Laura Chico | Wedbush | $31.00 | $14.47 | TheFly | Viridian Therapeutics price target lowered to $31 from $37 at Wedbush |
| February 26, 2026 3:36 pm | Kelly Shi | Jefferies | $45.00 | $28.80 | StreetInsider | Viridian Therapeutic (VRDN) PT Raised to $45 at Jefferies |
| January 28, 2026 11:41 am | Gavin Clark-Gartner | Evercore ISI | $45.00 | $33.14 | StreetInsider | Viridian Therapeutic (VRDN) PT Raised to $45 at Evercore ISI |
| January 20, 2026 1:20 pm | Gavin Clark-Gartner | Evercore ISI | $44.00 | $32.63 | TheFly | Viridian Therapeutics price target raised to $44 from $42 at Evercore ISI |
| January 7, 2026 1:23 pm | — | UBS | $50.00 | $30.82 | TheFly | Viridian Therapeutics initiated with a Buy at UBS |
| December 3, 2025 11:13 am | — | William Blair | $47.00 | $30.43 | TheFly | Viridian Therapeutics initiated with an Outperform at William Blair |
| November 24, 2025 12:20 pm | — | Truist Financial | $41.00 | $30.34 | TheFly | Viridian Therapeutics initiated with a Buy at Truist |
| November 6, 2025 6:55 pm | — | RBC Capital | $45.00 | $27.50 | TheFly | Viridian Therapeutics price target raised to $45 from $41 at RBC Capital |
| November 6, 2025 2:26 pm | — | Goldman Sachs | $40.00 | $28.11 | TheFly | Viridian Therapeutics price target raised to $40 from $30 at Goldman Sachs |
Latest News for VRDN
Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totaling 10,843,213 shares, an increase of 31.7% from the March 15th total of 8,233,141 shares. Approximately 10.8% of the shares of the stock are short sold. Based
Viridian Therapeutics, Inc. (NASDAQ: VRDN - Get Free Report) saw some unusual options trading activity on Monday. Traders acquired 7,501 put options on the company. This represents an increase of 3,294% compared to the typical daily volume of 221 put options. Wall Street Analyst Weigh In A number of research firms have recently weighed in on
The Phase 3 TEPEZZA OBI trial met its primary endpoint, showing a statistically significant 77% proptosis (bulging eyes) response rate among participants during the 24-week placebo-controlled period.
Amgen announces encouraging results in a Phase 3 trial for a new treatment of thyroid eye disease. Viridian Therapeutics is currently developing its own treatment for the disease.
Viridian Therapeutics, Inc. (VRDN) Discusses Positive Topline Results from Elegrobart REVEAL-1 Phase III Trial in Active Thyroid Eye Disease Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VRDN.
U.S. House Trading
No House trades found for VRDN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.